Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Novavax

The Biden administration supports suspending COVID-19 vaccine IP rights.

COVID-19 Vaccine Makers Slump After U.S. Supports Suspending IP Rights

Canaan Inc.

Block

Upland Software

Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. This time, our artificial intelligence systems have identified Moderna and IBM among other trending stocks.

Artificial Intelligence Ranks Moderna And IBM Among Trending Stocks

Moderna (MRNA) reports first profitable quarter on the back of its success with COVID-19 vaccine. The number of COVID-19 vaccine doses delivered in the first quarter add up to 102 million.

Moderna (MRNA) Beats on Q1 Earnings, Ups Vaccine Sales View

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna to present at the Bank of America 2021 Healthcare Conference.

Moderna to Present at the Bank of America 2021 Healthcare Conference

Moderna, Inc. (MRNA) CEO Stéphane Bancel on Q1 2021 Results - Earnings Call Transcript

BioNTech SE

Johnson & Johnson

Pfizer

AstraZeneca

Pfizer fell Thursday by as much as 5% from Wednesday's close while Moderna dipped by almost 12% before both stocks recovered most of those losses.

Covid vaccine makers' shares seesaw after Biden administration says it will back patent waivers

Moderna stock continued a two-day dive Thursday despite reporting its first profit after the first full quarter of Covid vaccine sales. But sales lagged forecasts.

Moderna's Bad News Just Got Worse — But There's A Silver Lining

Vaccine stocks — including BioNTech and Moderna stocks — pared deep losses Thursday after German Chancellor Angela Merkel said that she opposed waiving Covid vaccine patent rights. The post Vaccine Stocks Pare Deep Losses As Angela Merkel Opposes Waiving Patents appeared first on Investor's Business Daily.

Vaccine Stocks Pare Deep Losses As Angela Merkel Opposes Waiving Patents

It's been a complicated day for Moderna Inc. as the company reported its first-ever profit and its first-ever billion dollars in sales amidst an unprecedented move by the Biden administration to support waiving patent rights for COVID-19 vaccines.

Moderna's first-ever profit and billion-dollar quarter is dampened by COVID-19 vaccine patent proposal

Moderna (MRNA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Moderna (MRNA) Beat Estimates Again in Its Next Earnings Report?

Moderna Inc. (NASDAQ: MRNA) shares gapped down Thursday and have since gained back some ground. Moderna reported first-quarter earnings Thursday of $2.84 per share, beating the estimate of $2.39.

Moderna Stock Moves After Q1 Print: Technical Levels For The COVID-19 Vaccine Play

Fastly

Uber

When great results aren't enough for investors, stocks suffer.

Moderna Weighs Down the Stock Market; Uber, Fastly Fall

uniQure

Moderna, Inc. (NASDAQ: MRNA). uniQure N.V.

Why Moderna, uniQure And Novavax Are Moving Today

Even bigger profits could be on the way, despite worries about international waivers of the biotech's patents for its COVID-19 vaccine.

Moderna Posts Its First Profitable Quarter Ever in Q1

The US has backed a proposal first put forward by India and South Africa for a temporary waiver on COVID-19 vaccine patents. “The administration believes strongly in intellectual property protections, but in service of ending this pandemic, supports the waiver of those protections for COVID-19 vaccines,” said Ambassador Katherine Tai.

Moderna, Pfizer drop after US backs proposal to lift patent protection for COVID-19 vaccines to boost supply

The shares of Moderna Inc (NASDAQ:MRNA) are careening this morning, down 10.3% to trade $146.03, and brushing off the company's first-ever profit.

MRNA Plummets Despite Upbeat Earnings, Sales Forecast

Moderna (MRNA) delivered earnings and revenue surprises of 39.22% and -1.55%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Moderna (MRNA) Beats Q1 Earnings Estimates

The drug manufacturer announced its first profitable first quarter.

Moderna Says Covid-19 Vaccine Is 96% Effective In Teenagers, Will File For Full FDA Approval

Moderna fell 9% in pre-market trading on Thursday after reporting first-quarter earnings that missed analyst estimates. The therapeutics company reported $1.94 billion in net revenue for the three months ending in March, thanks to strong COVID-19 vaccine sales. That compared to revenue of $8 million for the same period last year, but fell short of the $2.04 billion analysts expected.

Moderna slumps 9% as the vaccine-maker's Q1 revenue misses estimates

Moderna CEO Stephane Bancel said Thursday the company expects more variants of the coronavirus will emerge in the coming months.

Moderna CEO expects more Covid variants to emerge in coming months: 'This virus is not going away'

Moderna's (MRNA) Q1 earnings exceeded analyst expectations, while revenue missed estimates. It was the company's first profitable quarter.

Moderna Q1 2021 Earnings Report Recap

Moderna Inc (NASDAQ: MRNA) reports Q1 EPS of $2.84, a turnaround from EPS loss of $0.35 a year ago, beating the consensus estimate of $2.39. However, Q1 revenues of $1.9 billion compared to $8 million a year ago fell short of the $2.04 billion consensus.

Moderna Stock Drops As Q1 Sales Fails To Meet Expectations; Anticipates $19.2B In FY21 Product Sales

Moderna Inc. said Thursday that initial data from the study evaluating its COVID-19 vaccine in teens between the ages of 12 and 17 years old showed an efficacy rate of 96%, with no serious safety concerns. The Phase 2/3 clinical trial is testing the vaccine in 3,235 teens who have received at least one shot in the two-dose regimen and have not previously been infected with SARS-CoV-2.

Moderna says its COVID-19 vaccine has a 96% efficacy rate in teens who have received one shot

Moderna Inc (NASDAQ:MRNA) and Pfizer Inc. (NYSE:PFE) had a double dose of good news regarding their COVID-19 vaccines. Moderna said that its tweaked jab was successful in neutralising the South African and Brazilian variants of the virus in laboratory trials.

Coronavirus: Moderna says tweaked vaccine works against variants, two BioNTech/Pfizer doses give 95% protection

Moderna Inc. brought in $1.7 billion in sales of its COVID-19 vaccine in the first quarter of 2021, marking the company's first significant billion-dollar revenue haul this year and also the first time it's ever reported a GAAP profit. Moderna had earnings of $1.2 billion, or $2.84 per share, in the first quarter of 2021.

News for Moderna Stock (MRNA)